Business Wire

FINARO

22.3.2022 17:40:03 CET | Business Wire | Pressemeddelelse

Del
Finaro udpeger Ruben Frimand Nielsen som Vicepræsident for Salg- & Forretningsudvikling for de Nordiske lande, som endnu et tiltag for at understøtte de ambitiøse vækstplaner

Finaro , den globale indløser og bank, der er specialister indenfor international handel, har i dag offentliggjort Ruben Frimand Nielsen som Vicepræsident for Salg- og Forretningsudvikling for de Nordiske lande.

Tidligere business manager hos Mastercard, Ruben, vil lede vækststrategien i Danmark, Sverige, Norge, Finland, Færøerne, Island og Grønland, side om side med udvidelsen af det globale Finaro-team. Inden han sluttede sig til Finaro, var Ruben ansvarlig for international porteføljeadministration, salg og produktstrategi, for afdelingen payments international hos Mastercard. Derfor er han klar til at bringe Finaros globale betalingsløsninger ud til virksomheder i en af de hurtigst voksende e-handels regioner i Europa.

Danske, svenske, norske og finske forbrugere brugte tilsammen 46,5 milliarder euro online i 2020, med 19% af de nordiske handlende der foretog online indkøb på tværs af grænserne . I Danmark købte mere end 90% af forbrugerne ind online i 2020, efterfulgt af 87% i Norge og 86% i Sverige . Disse tal forventes at stige i 2022, da forbrugerne har vænnet sig til disse indkøbsmetoder og gør brug af mobil handel såsom lokale digitale wallets og in-app payments.

Achiya Fried, Chief Commercial & Strategy Officer hos Finaro , fortæller: “Jeg er begejstret for, at byde Ruben velkommen. Vi har ambitiøse vækstplaner, og en central del af dette omfatter udvidelser i de Nordiske lande. Rubens betalingserfaring og viden indenfor strategi vil helt sikkert blive en af drivkrafterne for Finaros voksende fremdrift i regionen, og jeg ser frem til, at se hvad han kan gøre for teamet og for virksomheden.”

Igal Rotam, CEO for Finaro , siger: “Vi er begejstrede for, at Ruben slutter sig til vores virksomhed for at støtte denne vækst og udføre den strategiske plan for de Nordiske lande. Hans kompetencer og dybdegående indblik vil sikre, at Finaros kunder på det Nordiske marked har adgang til de innovative og banebrydende betalingsløsninger, som de har behov for, for at kunne betjene deres egne voksende globale kunder.”

Ruben Frimand Nielsen, Vicepræsident for Salg - & Forretningsudvikling hos Finaro, kommenterede om sin nye titel og arbejde : “Det er en utrolig spændende tid at blive en del af Finaro på og være en del af den stærke vækst og ambitiøse planer for fremtiden. Den varme velkomst, og mit eksisterende kendskab til virksomheden samt produkterne har givet mig en smidig overgang - og jeg ser frem til, at påtage mig rollen for væksten samt at sætte et fodaftryk på det Nordiske marked. Jeg ser frem til at komme i gang.’’

Rubens udnævnelse kommer efter det nylige skift af Finaros navn fra Credorax, der afspejler dens nye identitet og forpligtelse til at realisere dens vision for betalinger, hvor handel er uden landegrænser og fri for teknologiske, fysiske og geografiske begrænsninger. Efter et utroligt succesfuldt år i 2021, med mere end 10 milliarder US dollars i samlet behandlet volume for mere end 5.000 handelsdrivende, er Finaro dedikeret til at gøre komplekse betalinger enkle, kombineret med dens instinktive passion for kundeservice, som går langt videre end det normale.

Om Finaro

Finaro er en global betalingsudbyder der på tværs af landegrænser styrker den internationale handel gennem enkle betalinger og innovativ teknologi. Vores dedikerede team, enestående teknologiske formåen, produktinnovation og kundefokuserede tilgang, gør os i stand til at forenkle kompleksitet og skabe samlet købsoplevelse der medfører vækst og giver ro i sindet for vores kunder. For at lære mere kan du besøge www.finaro.com .

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye